Novo Nordisk Committed To Advancing In Cardiovascular
As Ziltivekimab Shows Promise
The Danish major’s head of development tells Scrip that as cardiovascular disease is very closely related to obesity and diabetes, Novo Nordisk has the expertise to thrive in the former.
You may also be interested in...
Novo's head of rare disease Ludovic Helfgott talked to Scrip about the $1.1bn acquisition and expansion into sickle cell disease.
Danish pharma says it will not market the weight-loss formulation of semaglutide until manufacturing can meet demand. Novo has seen significant growth in GLP-1 franchise in both diabetes and obesity.
The deal leaves PRX004 in the capable hands of Novo Nordisk, which is hoping to expand beyond obesity and diabetes, while Prothena can focus on the rest of its pipeline.